[go: up one dir, main page]

AR066125A1 - Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal - Google Patents

Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal

Info

Publication number
AR066125A1
AR066125A1 ARP080101626A ARP080101626A AR066125A1 AR 066125 A1 AR066125 A1 AR 066125A1 AR P080101626 A ARP080101626 A AR P080101626A AR P080101626 A ARP080101626 A AR P080101626A AR 066125 A1 AR066125 A1 AR 066125A1
Authority
AR
Argentina
Prior art keywords
cycloalkenyl
cycloalkyl
alkyl
heterocycloalkenyl
heteroaryl
Prior art date
Application number
ARP080101626A
Other languages
English (en)
Inventor
Xumiao Zhao
Christopher Autry
Catherine Hulford
Matthew Hayward
Samit BHATTACHARYA
Christopher R Nelson
Kevin Freeman-Cook
Jun Xiao
Michael LUZZIO
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR066125A1 publication Critical patent/AR066125A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto caracterizado porque es de formula 1, o una sal farmacéuticamente aceptable del mismo; en la que A es un resto anillo seleccionado entre el grupo constituido por: (a) carbociclilo de 4 a 7 miembros, (b) heterociclilode 4 a 7 miembros, (c) fenilo, y (d) anillo de heteroarilo de 5 a 6 miembros, en el que cada uno de dicho carbociclilo de 4 a 7 miembros y heterociclilo de 4 a 7 miembros de dicho grupo A puede contener opcionalmente uno o dos enlaces olefínicos; yen el que uno o dos átomos de carbono en el anillo en cada uno de dicho carbociclilo de 4 a 7 miembros y heterociclilo de 4 a 7 miembros de dicho grupo A puede reemplazarse independientemente opcionalmente por uno o dos restos seleccionadosindependientemente entre el grupo constituido por -C(O)-, -C(S)- y -C(=NR4)-; B es fenilo o un heteroarilo de 5 a 6 miembros; K es CH, C(NH2) o N; cada R1 se selecciona independientemente entre el grupo constituido por -H, halo, -CF3, -CN, -NO2, -NR7R8, NR7C(NR7R8)(=CR9), -CR7(NR7R8)(=NR7), -NR7C(NR7R8)(=NR7), -NR7C(O)R9, -C(O)NR7R8, -C(O)R9, -C(O)C(O)R9, -C(O)OR10, -OC(O)R9, -OR10, -OC(O)OR10, -S(O)jR11, -S(O)(=NR7)R8, -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -cicloalquenilo C5-10, -bicicloalquilo C6-10, -bicicloalquenilo C6-10, -heterocicloalquilo C1-9, -heterocicloalquenilo C4-9, -heterobicicloalquilo C6-9, -heterobicicloalquenilo C6-9, -arilo C6-10, y -heteroarilo C1-9; y en el que cada uno de losrestos anteriores -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -cicloalquenilo C5-10, -heterocicloalquilo C1-9, -heterocicloalquenilo C4-9, -arilo C6-10, y -heteroarilo C1-9; de dicho R1 está sustituido opcionalmenteindependientemente con de uno a tres grupos R12; cada uno de R2 y R3 se selecciona independientemente entre el grupo constituido por -H, -halo, -OR10, -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -cicloalquenilo C5-10, -heterocicloalquilo C2-9, -heterocicloalquenilo C4-9, -arilo C6-10 y -heteroarilo C1-9; y en el que cada uno de los restos anteriores -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -cicloalquenilo C5-10, -heterocicloalquilo C2-9, -heterocicloalquenilo C4-9, -arilo C6-10 y -heteroarilo C1-9 de dichos R2 y R3 está opcionalmente sustituido con de uno a tres grupos R12; cada uno de R4 y R5 se selecciona independientemente entre el grupo constituido por -H, -NR7R8, -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -cicloalquenilo C5-10, -heterocicloalquilo C2-9, - heterocicloalquenilo C4-9, -arilo C6-10 y -heteroarilo C1-9; y en el que cada uno de los restos anteriores -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -cicloalquenilo C5-10, -heterocicloalquilo C2-9, - heterocicloalquenilo C4-9, -arilo C6-10 y -heteroarilo C1-9 de dichos R4 y R5 está opcionalmente sustituido con de uno a tres grupos R12; R6 se selecciona entreel grupo constituido por -halo, -NR7R8, -OR10, -C(O)R9, -CO2R10, -CONR7R8, -S(O)jR11, -NR7CONR7R8, y -NR8SO2R11, -NO2, -CN, -CF3, -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -alquilo C2-6 perfluorado, -alquenilo C2-6 perfluorado, -alquinilo C3-6 perfluorado, -cicloalquilo C3-7, -cicloalquenilo C5-10, -bicicloalquilo C6-10, -bicicloalquenilo C6-10, -heterociclilo C1-9, -heterocicloalquenilo C1-10, -heterobicicloalquilo C6-9, -heterobicicloalquenilo C6-9, -arilo C6-10, -heteroarilo C1-9, -arilo C6-10 perfluorado, y -heteroarilo C1-9 perfluorado; y en el que cada uno de dichos restos -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-7, -cicloalquenilo C5-10, -bicicloalquilo C6-10, -bicicloalquenilo C6-10, -heterociclilo C1-9, -heterocicloalquenilo C1-10, -heterobicicloalquilo C6-9, -heterobicicloalquenilo C6-9, -arilo C6-10, y -heteroarilo C1-9, de dicho R6 está opcionalmente sustituido con de uno a tres grupos R12; cada uno de R7 y R8 se seleccionaindependientemente entre el grupo constituido por -H, -OR10, -S(O)jR11, -NO2, -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -cicloalquenilo C5-10, -bicicloalquilo C6-10, -bicicloalquenilo C6-10, -heterocicloalquilo C2-9, -heterocicloalquenilo C4-9, -heterobicicloalquilo C6-9, heterobicicloalquenilo C6-9, -arilo C6-10, y -heteroarilo C1-9; y en el que cada uno de los restos anteriores -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -cicloalquenilo C5-10, -heterocicloalquilo C2-9, -heterocicloalquenilo C4-9, -arilo C6-10 y -heteroarilo C1-9 de dichos R7 y R8 está opcionalmente sustituido con de uno a tres grupos R12; cada R9 se selecciona independientemente entre el grupoconstituido por -H, -halo, -NR13R14, -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -cicloalquenilo C5-10, -bicicloalquilo C6-10, bicicloalquenilo C6-10, -heterocicloalquilo C2-9, -heterocicloalquenilo C4-9, -heterobicicloalquilo C6-9, -heterobicicloalquenilo C6-9, -arilo C6-10 y -heteroarilo C1-9; y en el que cada uno de los restos anteriores -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -cicloalquenilo C5-10, -heterocicloalquiloC2-9, -heterocicloalquenilo C4-9, -arilo C6-10 y -heteroarilo C1-9 de dicho R9 está opcionalmente sustituido con de uno a tres grupos R12; cada R10 se selecciona independientemente entre el grupo constituido por -H, -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -cicloalquenilo C5-10, -bicicloalquilo C6-10, -bicicloalquenilo C6-10, - heterocicloalquilo C2-9, -heterocicloalquenilo C4-9, -heterobicicloalquilo C6-9, -heterobicicloalquenilo C6-9, -arilo C6-10, y -heteroariloC1-9; y en el que cada uno de los restos anteriores -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -cicloalquenilo C5-10, - heterocicloalquilo C2-9, -heterocicloalquenilo C4-9, -arilo C6-10 y -heteroarilo C1-9 de dicho R10está opcionalmente sustituido con de uno a tres grupos R12; cada R11 se selecciona independientemente entre el grupo constituido por -H, -NR13R14, -C(O)R13, -CF3, -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -cicloalqueniloC5-10, -bicicloalquilo C6-10, -bicicloalquenilo C6-10, - heterocicloalquilo C2-9, -heterocicloalquenilo C4-9, -heterobicicloalquilo C6-9, -heterobicicloalquenilo C6-9, -arilo C6-10, y -heteroarilo C1-9; y en el que cada uno de los restos anteriores -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -cicloalquenilo C5-10, - heterocicloalquilo C2-9, -heterocicloalquenilo C4-9, -arilo C6-10 y -heteroarilo C1-9 de dicho R10 está opcionalmente sustituido con de uno a tres gruposR12; cada R12 se selecciona independientemente entre el grupo constituido por -H, -OR13, -C(O)R13, -C(O)OR13, -OC(O)R13, -OC(O)OR13, -C(O)NR13R14, -NR13C(O)NR13R14, -NR13R14, -NR13C(NR13R14)(=NR13), -NR13C(NR13R14)(=N-C(O)R13), -NR13C(O)R14, -NR13S(O)jR13, -S(O)jR13, -CF3, -CN, -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -cicloalquenilo C5-10, -bicicloalquilo C6-10, bicicloalquenilo C6-10, -heterocicloalquilo C2-9, -heterocicloalquenilo C4-9, -heterobicicloalquilo C6-9, -heterobicicloalquenilo C6-9, -arilo C6-10 y -heteroarilo C1-9; en el que cada uno de los anteriores -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -cicloalquenilo C5-10, -bicicloalquilo C6-10,bicicloalquenilo C6-10, -heterocicloalquilo C2-9, -heterocicloalquenilo C4-9, -heterobicicloalquilo C6-9, -heterobicicloalquenilo C6-9, -arilo C6-10 y -heteroarilo C1-9 de dicho R12 están sustituido opcionalmente independientemente con de uno a tresgrupos seleccionados entre el grupo constituido por -halo, -CF3, -CN, -NO2, -OH, -O(alquilo C1-6), -C(O)R15, C(O)NR15R16, -S(O)jR15, y -S(O)jNR15R16, -cicloalquilo C3-10, -heterocicloalquilo C2-9, -SH, -S(alquilo C1-6), -NH2,-NH(alquilo C1-6) y -N(alquilo C1-6)2; cada uno de R13 y R14 se selecciona independientemente entre el grupo constituido por -H, -NR15C(O)R16, -CF3, -CN, -S(O)jR15, -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -cicloalquenilo C5-10, -bicicloalquilo C6-10, -bicicloalquenilo C6-10, -heterocicloalquilo C2-9, -heterocicloalquenilo C4-9, -heterobicicloalquilo C6-9, -heterobicicloalquenilo C6-9, -arilo C6-10, y -heteroarilo C1-9; y en el que cada uno de los anteriores -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -cicloalquenilo C5-10, -bicicloalquilo C6-10, -bicicloalquenilo C6-10, -heterocicloalquilo C2-9, -heterocicloalquenilo C4-9, -heterobicicloalquilo C6-9, -heterobicicloalquenilo C6-9, -arilo C6-10, y -heteroarilo C1-9 de dichos R13 y R14 están sustituidos opcionalmente independientemente con de uno a tres grupos seleccionados entre el grupo constituido por -halo, -CF3, -CN, -NO2, -OH, -O(alquilo C1-6), -C(O)(alquilo C1-6), -cicloalquilo C3-10, heterocicloalquilo C2-9, -SH, -S(alquilo C1-6), -NH2, -NH(alquilo C1-6) y-N(alquilo C1-6)2; cada uno de R15 y R16 se selecciona independientemente entre el grupo constituido por -H, -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquiloC3-10, -cicloalquenilo C5-10, -bicicloalquilo C6-10, -bicicloalquenilo C6-10, -heterocicloalquilo C2-9, -heterocicloalquenilo C4-9, -heterobicicloalquilo C6-9, -heterobicicloalquenilo C6-9, -arilo C6-10, y -heteroarilo C1-9; y en el que cada uno delos anteriores -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -cicloalquenilo C5-10, -bicicloalquilo C6-10, -bicicloalquenilo C6-10, -heterocicloalquilo C2-9, -heterocicloalquenilo C4-9, -heterobicicloalquilo C6-9, -heterobicicloalquenilo C6-9, -arilo C6-10, y -heteroarilo C1-9 de dichos R15 y R16 están sustituidos opcionalmente independientemente con de uno a tres grupos seleccionados entre el grupo constituido por -halo, -CF3, -CN, -NO2, -OH, -O(alquilo C1-6), -C(O)(alquilo C1-6), -cicloalquilo C3-10, heterocicloalquilo C2-9, -SH, -S(alquilo C1-6), -NH2, -NH(alquilo C1-6) y-N(alquilo C1-6)2; en el que uno o dos átomos de carbono en el anillo en
ARP080101626A 2007-04-18 2008-04-18 Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal AR066125A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91259707P 2007-04-18 2007-04-18

Publications (1)

Publication Number Publication Date
AR066125A1 true AR066125A1 (es) 2009-07-22

Family

ID=39646361

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101626A AR066125A1 (es) 2007-04-18 2008-04-18 Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal

Country Status (32)

Country Link
US (13) US7928109B2 (es)
EP (1) EP2146779B1 (es)
JP (1) JP4782239B2 (es)
KR (1) KR101132880B1 (es)
CN (2) CN103951658B (es)
AP (1) AP2009005010A0 (es)
AR (1) AR066125A1 (es)
AU (1) AU2008240359B2 (es)
BR (1) BRPI0810411B8 (es)
CA (1) CA2684447C (es)
CL (1) CL2008001076A1 (es)
CO (1) CO6260093A2 (es)
CU (1) CU23813A3 (es)
DK (1) DK2146779T3 (es)
DO (1) DOP2009000248A (es)
EA (1) EA016679B1 (es)
EC (1) ECSP099694A (es)
ES (1) ES2593486T3 (es)
GE (1) GEP20125581B (es)
GT (1) GT200900272A (es)
IL (3) IL201468A (es)
MA (1) MA31319B1 (es)
MX (1) MX2009011090A (es)
NI (1) NI200900190A (es)
NZ (1) NZ580372A (es)
PA (1) PA8777101A1 (es)
PE (1) PE20090434A1 (es)
TN (1) TN2009000428A1 (es)
TW (1) TWI369205B (es)
UA (1) UA97834C2 (es)
UY (1) UY31026A1 (es)
WO (1) WO2008129380A1 (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4782239B2 (ja) 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
UY31714A (es) * 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
CA2718858A1 (en) * 2008-03-20 2009-09-24 Boehringer Ingelheim International Gmbh Selective synthesis of substituted pyrimidines
US20100056524A1 (en) * 2008-04-02 2010-03-04 Mciver Edward Giles Compound
EA201100436A1 (ru) * 2008-09-03 2011-10-31 Байер Кропсайенс Аг Гетероциклически замещенные анилинопиримидины в качестве фунгицидов
UY32240A (es) * 2008-11-14 2010-06-30 Boeringer Ingelheim Kg Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
JP2010111702A (ja) 2009-02-16 2010-05-20 Tetsuya Nishio 複素環化合物、その製造法および用途
CN101812016B (zh) * 2009-02-23 2013-01-16 浙江海翔药业股份有限公司 一种制备依托昔布中间体-6-甲基烟酸及其酯的方法
EP2261211A1 (en) * 2009-05-20 2010-12-15 Université de Lille 2 Droit et Santé 1,4-dihydropyridine derivatives and their uses
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
WO2010141796A2 (en) 2009-06-05 2010-12-09 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
WO2011018517A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2542536B1 (en) 2010-03-04 2015-01-21 Cellzome Limited Morpholino substituted urea derivatives as mtor inhibitors
RU2528386C2 (ru) 2010-05-21 2014-09-20 Кемилиа Аб Новые производные пиримидина
HUE029196T2 (en) * 2010-06-04 2017-02-28 Hoffmann La Roche Aminoprimidine derivatives as LRRK2 modulators
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
PT2646448T (pt) 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Inibidores macrocíclicos de cinases
CA2827172C (en) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
CA2830129C (en) 2011-03-24 2016-07-19 Chemilia Ab Novel pyrimidine derivatives
SG10201702654VA (en) 2011-04-22 2017-06-29 Signal Pharm Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
RU2564419C1 (ru) * 2011-07-28 2015-09-27 Целльзом Лимитид Гетероциклические аналоги пиримидина в качестве ингибиторов jak
WO2013014162A1 (en) 2011-07-28 2013-01-31 Cellzome Limited Heterocyclyl pyrimidine analogues as jak inhibitors
BR112014006743A8 (pt) 2011-09-21 2018-01-09 Cellzome Ltd composto, uso de um composto, e, método para tratar, controlar, retardar ou impedir uma ou mais condições
US9242993B2 (en) 2011-10-07 2016-01-26 Cellzome Limited Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors
CN104169272A (zh) 2011-12-23 2014-11-26 赛尔佐姆有限公司 作为激酶抑制剂的嘧啶-2,4-二胺衍生物
HUE027976T2 (en) * 2012-03-06 2016-11-28 Cephalon Inc Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
US9296725B2 (en) 2012-05-24 2016-03-29 Cellzome Limited Heterocyclyl pyrimidine analogues as TYK2 inhibitors
EP3091981B1 (en) * 2014-01-09 2021-03-10 Verastem, Inc. Compositions and methods for treatment of abnormal cell growth
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
JP2017505321A (ja) * 2014-02-07 2017-02-16 ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． 異常な細胞成長を処置するための方法および組成物
GEP20186921B (en) 2014-05-14 2018-11-12 Pfizer Pyrazolopyridines and pyrazolopyrimidines
SG11201704827UA (en) 2014-12-16 2017-07-28 Signal Pharm Llc Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
EP3233808B1 (en) 2014-12-16 2021-07-14 Signal Pharmaceuticals, LLC Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin
WO2016100452A2 (en) * 2014-12-17 2016-06-23 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2016123291A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CA3244408A1 (en) 2015-06-29 2025-06-13 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
MX2018001004A (es) 2015-07-24 2018-06-07 Celgene Corp Metodos de sintesis de clorhidrato de (1r,2r,5r)-5-amino-2-metilci clohexanol e intermedios utiles en este.
CN105111204B (zh) * 2015-08-14 2016-09-14 天津小新医药科技有限公司 吡啶盐类酪氨酸激酶抑制剂、制备方法及其用途
CN105153150B (zh) * 2015-08-14 2016-09-14 天津小新医药科技有限公司 一类吡啶盐类jak抑制剂、制备方法及其用途
CN105503860B (zh) * 2015-10-13 2017-03-01 天津小新医药科技有限公司 一类腈基取代的吡啶盐类jak抑制剂、制备方法及其用途
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CN106279011A (zh) * 2016-08-16 2017-01-04 成都百事兴科技实业有限公司 一种2,4‑二羟基‑6‑甲基烟酸乙酯的制备方法
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
CN112218658A (zh) 2018-03-12 2021-01-12 国家健康科学研究所 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
US11891379B2 (en) 2018-05-07 2024-02-06 Hinova Pharmaceuticals Inc. Deuterated Defactinib compound and use thereof
WO2020006724A1 (zh) * 2018-07-05 2020-01-09 清华大学 一种靶向降解fak蛋白的化合物及其应用
WO2020069117A1 (en) * 2018-09-27 2020-04-02 Dana-Farber Cancer Institute, Inc. Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use
US12194040B2 (en) * 2018-12-27 2025-01-14 Hinova Pharmaceuticals Inc. FAK inhibitor and drug combination thereof
WO2021047783A1 (en) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
CA3174992A1 (en) * 2020-03-02 2021-09-10 Sironax Ltd. Ferroptosis inhibitors - diarylamine para-acetamides
IL303237A (en) * 2020-11-27 2023-07-01 Anrui Biomedical Tech Guangzhou Co Ltd Aminoheteroaryl kinase inhibitors
CN112592318B (zh) * 2020-12-12 2022-05-03 贵州医科大学 2-(4-甲氨酰基)苯胺基-4-氨基嘧啶衍生物及应用
CN112624966B (zh) * 2020-12-25 2022-12-23 杭州澳赛诺生物科技有限公司 一种2-氨甲基-4-甲基-5-吡啶羧酸的合成方法
CA3208625A1 (en) * 2021-01-18 2022-07-21 Hinova Pharmaceuticals Inc. Synthesis method for aminopyrimidine fak inhibitor compound
CN113372334B (zh) * 2021-05-25 2022-05-03 贵州医科大学 2-(4-甲氨酰基)苯胺基-4-氨基-5-三氟甲基嘧啶衍生物及其应用
US20240277710A1 (en) * 2021-05-25 2024-08-22 Hinova Pharmaceuticals Inc. Pharmaceutical composition for treatment of cancer and use thereof
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN114716385B (zh) * 2022-04-08 2024-03-12 北京师范大学 靶向粘着斑激酶的化合物及制备方法和应用
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
JPWO2024071371A1 (es) * 2022-09-30 2024-04-04
WO2024249831A2 (en) * 2023-06-02 2024-12-05 Unogen Biotech Ltd. Triple kinase inhibitors
CN117105916B (zh) * 2023-10-23 2024-01-16 希格生科（深圳）有限公司 苯并呋喃类化合物及其医药用途
WO2025166124A1 (en) * 2024-02-02 2025-08-07 Deciphera Pharmaceuticals, Llc Ulk inhibitors and methods of use thereof
WO2025166180A1 (en) * 2024-02-02 2025-08-07 Deciphera Pharmaceuticals, Llc Ulk inhibitors and methods of use thereof
EP4688771A1 (en) 2024-03-22 2026-02-11 Bristol-Myers Squibb Company Novel fak degrader compounds and uses thereof

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507146A (en) 1982-12-28 1985-03-26 Ciba-Geigy Corporation 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
CN1142817A (zh) 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1n-烷基-n-芳基嘧啶胺及其衍生物
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US5861510A (en) 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
DE69624081T2 (de) 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ES2191187T3 (es) 1996-07-13 2003-09-01 Glaxo Group Ltd Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
EA199900036A1 (ru) 1996-07-18 1999-06-24 Пфайзер Инк Ингибиторы металлопротеаз матрикса на основе фосфинатов, фармацевтическая композиция, способ лечения
PL331895A1 (en) 1996-08-23 1999-08-16 Pfizer Arylosulphonylamino derivatives of hydroxamic acid
DK0950059T3 (da) 1997-01-06 2004-11-01 Pfizer Cycliske sulfonderivater
ATE248812T1 (de) 1997-02-03 2003-09-15 Pfizer Prod Inc Arylsulfonylhydroxamsäurederivate
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
PL334997A1 (en) 1997-02-11 2000-03-27 Pfizer Derivatives or arylosulphonyl-hydroxamic acid
BR9811868A (pt) 1997-08-08 2000-08-15 Pfizer Prod Inc Derivados de ácido ariloxiarilsulfonilamino hidroxâmico
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
IL137922A0 (en) 1998-02-17 2001-10-31 Tularik Inc Anti-viral pyrimidine derivatives
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
IT1302431B1 (it) * 1998-08-12 2000-09-05 Alasi Di Arcieri Franco & C S Dispositivo di controllo di accessi in rete tramite il riconoscimentoveloce di trame applicative che soddisfano un insieme di regole
ES2213985T3 (es) 1998-11-05 2004-09-01 Pfizer Products Inc. Derivados de hidroxiamida de acido 5-oxo-pirrolidin-2-carboxilico.
WO2000042003A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0004888D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
CA2406562C (en) 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
CA2407754C (en) 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Prodrugs of hiv replication inhibiting pyrimidines
US6630469B2 (en) * 2000-05-09 2003-10-07 Bristol-Myers Squibb Company 5-HT7 receptor antagonists
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US6853233B1 (en) * 2000-09-13 2005-02-08 Infineon Technologies Ag Level-shifting circuitry having “high” output impedance during disable mode
IT1319686B1 (it) 2000-12-12 2003-10-23 C D Farmasint S R L Procedimento di preparazione di citalopram.
CN102250071A (zh) 2000-12-21 2011-11-23 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
DE50213202D1 (de) * 2001-05-29 2009-02-26 Bayer Schering Pharma Ag Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
WO2002102783A1 (en) 2001-06-19 2002-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1397142A4 (en) * 2001-06-19 2004-11-03 Bristol Myers Squibb Co PYRIMIDINE PHOSPHODIESTERASE (PDE) INHIBITORS 7
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003040141A1 (en) 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
WO2003032997A1 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7008378B2 (en) * 2002-03-07 2006-03-07 Dean Melanie A Patient conditional diagnosis assessment and symptom tracking system
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) * 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
AU2003244098A1 (en) * 2002-06-28 2004-01-19 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxa mide derivative
NZ537752A (en) 2002-07-29 2006-12-22 Rigel Pharmaceuticals Inc Use of 2,4-pyrimidinediamine compounds in the preparation of medicaments for treating autoimmune diseases
JP2006507302A (ja) 2002-10-30 2006-03-02 メルク　エンド　カムパニー　インコーポレーテッド キナーゼ阻害剤
US7504410B2 (en) * 2002-11-28 2009-03-17 Schering Aktiengesellschaft Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
AU2003285614B2 (en) * 2002-12-20 2009-05-14 Pfizer Products, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) * 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
SE0203820D0 (sv) * 2002-12-20 2002-12-20 Astrazeneca Ab chemical compounds
NZ541902A (en) 2003-02-07 2008-12-24 Janssen Pharmaceutica Nv Pyrimidine derivatives for the prevention of HIV infection
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2005003103A2 (en) 2003-06-30 2005-01-13 Astrazeneca Ab 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
WO2005009980A1 (en) 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
EP2287156B1 (en) 2003-08-15 2013-05-29 Novartis AG 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
PL1663991T3 (pl) * 2003-09-05 2007-04-30 Pfizer Prod Inc Selektywna synteza CF3 – podstawionych pirymidyn
US7363505B2 (en) * 2003-12-03 2008-04-22 Pen-One Inc Security authentication method and system
JP2007537230A (ja) * 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の処置用のピリミジン誘導体
MXPA06011890A (es) * 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para tratar el crecimiento celular anomalo.
JP2007537238A (ja) * 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療のためのピリミジン誘導体
WO2005111024A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
ATE415397T1 (de) 2004-06-04 2008-12-15 Arena Pharm Inc Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
EP1765325A4 (en) 2004-07-01 2009-08-12 Synta Pharmaceuticals Corp HETEROARYL COMPOUNDS SUBSTITUTED IN 2
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
RU2007114080A (ru) * 2004-10-13 2008-11-27 Вайет (Us) N-бензилсульфонил-замещенные аналоги анилинопиримидина
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
WO2006053112A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Process for preparing trisubstituted pyrimidine compounds
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
US8722884B2 (en) 2005-12-01 2014-05-13 Verastem, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
RS20080272A (sr) * 2005-12-21 2009-07-15 Pfizer Products Inc., Derivati pirimidina za tretman neprirodnog rasta ćelija
JP4782239B2 (ja) * 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体

Also Published As

Publication number Publication date
CN103951658A (zh) 2014-07-30
US20090054395A1 (en) 2009-02-26
EP2146779B1 (en) 2016-08-10
US8440822B2 (en) 2013-05-14
JP2010524914A (ja) 2010-07-22
IL201468A0 (en) 2010-05-31
HK1200450A1 (en) 2015-08-07
NI200900190A (es) 2010-01-27
US20190047979A1 (en) 2019-02-14
US20200002310A1 (en) 2020-01-02
CU20090175A7 (es) 2011-09-21
IL232511B (en) 2018-07-31
CN103951658B (zh) 2017-10-13
US20170001981A1 (en) 2017-01-05
US20160130250A1 (en) 2016-05-12
TN2009000428A1 (fr) 2011-03-31
DK2146779T3 (en) 2016-11-28
AP2009005010A0 (en) 2009-10-31
EP2146779A1 (en) 2010-01-27
PA8777101A1 (es) 2008-11-19
KR101132880B1 (ko) 2012-06-28
US7928109B2 (en) 2011-04-19
NZ580372A (en) 2012-01-12
EA016679B1 (ru) 2012-06-29
US20110166120A1 (en) 2011-07-07
TWI369205B (en) 2012-08-01
GEP20125581B (en) 2012-07-25
KR20090130248A (ko) 2009-12-21
UA97834C2 (ru) 2012-03-26
US20150080368A1 (en) 2015-03-19
AU2008240359A1 (en) 2008-10-30
JP4782239B2 (ja) 2011-09-28
BRPI0810411A2 (pt) 2014-10-14
ECSP099694A (es) 2009-11-30
PE20090434A1 (es) 2009-04-13
EA200901250A1 (ru) 2010-04-30
US20240109862A1 (en) 2024-04-04
MA31319B1 (fr) 2010-04-01
BRPI0810411B1 (pt) 2019-09-10
US20250214963A1 (en) 2025-07-03
ES2593486T3 (es) 2016-12-09
GT200900272A (es) 2010-05-17
CO6260093A2 (es) 2011-03-22
HK1136985A1 (en) 2010-07-16
US10450297B2 (en) 2019-10-22
MX2009011090A (es) 2009-11-02
CN101678215B (zh) 2014-10-01
DOP2009000248A (es) 2009-11-15
US8247411B2 (en) 2012-08-21
AU2008240359B2 (en) 2014-06-26
CN101678215A (zh) 2010-03-24
BRPI0810411B8 (pt) 2021-05-25
UY31026A1 (es) 2008-11-28
US20130005964A1 (en) 2013-01-03
CA2684447A1 (en) 2008-10-30
WO2008129380A1 (en) 2008-10-30
US20140100368A1 (en) 2014-04-10
IL201468A (en) 2014-06-30
US20170327485A1 (en) 2017-11-16
CL2008001076A1 (es) 2008-10-24
TW200848050A (en) 2008-12-16
CA2684447C (en) 2012-01-24
CU23813A3 (es) 2012-06-21
IL260560B (en) 2021-04-29
US20220251066A1 (en) 2022-08-11
IL232511A0 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
AR066125A1 (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal
ES2505091T3 (es) Compuestos, composiciones y métodos de uso de ftalazina
AR060994A1 (es) Derivados de triazolopirazina
ES2564179T3 (es) Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales
AR070343A1 (es) Piridinil amidas, un procedimiento para el tratamiento de la esquizofrenia en un mamifero y una composicion farmaceutica
AR059621A1 (es) Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1
AR060401A1 (es) Derivados de cromen-2-ona
AR087196A1 (es) Metodos plaguicidas que utilizan compuestos de 3-piridil tiazol sustituido y derivados para combatir las plagas de animales ii
PE20141041A1 (es) Compuestos, metodos y formulaciones parasiticidas
ES2571479T3 (es) Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
AR081797A1 (es) Derivados de pirrolidinona heteroaromaticas fusionadas, composiciones farmaceuticas que las contienen y uso de las mismas para tratar afecciones del sistema inmune y la inflamacion
CY1112006T1 (el) Μακροκυκλικοι αναστολεις του ιου της ηπατιτιδας c
AR074109A1 (es) Pirrolidinas heterociclicas agonistas de receptores de la melanocortina, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la obesidad, diabetes y disfuncion erectil.
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
CO6270320A2 (es) Derivados de piperidina utiles como antagonistas del receptor orexina
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
PE20130155A1 (es) Derivados de ariletinilo
AR054809A1 (es) Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa
CO6351734A2 (es) Compuestos de amida utiles en terapia
AR073990A1 (es) Derivados de fenilamida y piridilamida
ECSP099461A (es) Compuesto heteromonocíclico y uso del mismo
AR083635A1 (es) Compuestos y derivados sustituidos de isoxazolina que contienen azolin para combatir plagas animales
ES2606197T3 (es) Moduladores pirrolidina de GPR40
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp

Legal Events

Date Code Title Description
FA Abandonment or withdrawal